Researchers at Helmholtz Munich have engineered a hybrid obesity drug that uses GLP-1 receptors to smuggle a second metabolic compound directly into cells, outperforming standard treatments in mice.
Scientists have developed a hybrid obesity compound that uses the same GLP-1/GIP signalling route targeted by Ozempic-style drugs to deliver a second metabolic drug into specific cells.
The molecule, described in a preclinical Nature study, combines a GLP-1/GIP incretin component with lanifibranor, a pan-PPAR agonist that acts on metabolic switches involved in fat handling, insulin sensitivity and glucose control.
The conventional path for combination obesity drugs has been to dose two compounds in parallel and hope the side effects do not stack. This reported approach took a different route: chemically tethering the PPAR drug to an incretin molecule that binds to GLP-1 and GIP receptors.
In simple terms, the incretin acts like an address label. It binds to GLP-1R or GIPR on the cell surface, helps the hybrid molecule enter the cell, and then allows the PPAR component to act inside cells that express those receptors.
The result is a single molecule designed to hit five pathways at once: two cell-surface receptors, GLP-1R and GIPR, and three intracellular PPAR targets, PPARα, PPARγ and PPARδ.
In diet-induced obese mice, the hybrid molecule outperformed GLP-1/GIP co-agonism and semaglutide in reducing body weight, food intake and high blood glucose, according to the Nature paper. The researchers also reported improved glucose tolerance and insulin sensitivity in the mouse experiments.
A Helmholtz Munich summary of the work said the team’s goal was to enhance incretin activity without creating a second system-wide source of side effects.
That matters because PPAR-targeting drugs can be limited by safety concerns when they circulate broadly through the body. By attaching the PPAR component to an incretin delivery system, the researchers were trying to concentrate the added metabolic effect in GLP-1R/GIPR-expressing cells rather than exposing the whole body to a separate drug at full systemic dose.
The caveats are important. This was a mouse study, not a human trial. The Nature paper also notes that the biology of these pathways is complex, and results in mice do not guarantee the same balance of weight loss, glucose control and tolerability in people.
Still, the design logic is notable. GLP-1 drugs have already reshaped obesity and type 2 diabetes treatment, and pharmaceutical companies are racing to engineer the next generation. This approach is interesting less because this exact molecule is ready for patients, and more because it shows a possible new route for multi-target metabolic drugs: using incretin receptors as a delivery system rather than simply stacking separate compounds.
If that idea translates beyond preclinical models, it could help researchers explore stronger combination therapies while trying to avoid the side-effect ceiling that has limited some metabolic drug classes in the past.
